CYPROHEPTADINE HCL EFFECT ON FAILURE TO THRIVE

盐酸赛庚啶对生长失败的影响

• 批准号: 6282658
• 负责人: MICHAEL KAPLAN
• 金额: $ 0.62万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6282658
• 关键词: body weight; chemotherapy; clinical research; clinical trials; cyproheptadine; drug screening /evaluation; family structure /dynamics; human subject; human therapy evaluation; infant human (0-1 year); pediatric pharmacology; postnatal growth disorder; socioenvironment

Children with nonorganic failure to thrive present a difficult challenge to the pediatrician as there is no specific treatment once organic etiologies have been ruled out. This study is investigating whether Cyproheptadine HCL (Periactin), an antihistamine with appetite stimulating effects, will promote weight gain in children with nonorganic failure to thrive. Weight gain in these children will be evaluated to determine if it is due to a physiological effect of the medication or to an improvement in psychosocial functioning in the family.

非器质性缺陷的儿童无法茁壮成长， 因为一旦有了器质性病变， 病因已被排除。 这项研究正在调查是否 赛庚啶盐酸盐（Periactin），一种抗组胺药，具有食欲刺激作用 影响，将促进非器质性衰竭儿童的体重增加， 茁壮成长 将对这些儿童的体重增加进行评估，以确定 这是由于药物的生理作用或改善 在家庭中的社会心理功能。